Corbus Pharmaceuticals (NASDAQ:CRBP) Given “Outperform” Rating at Mizuho

Corbus Pharmaceuticals (NASDAQ:CRBP)‘s stock had its “outperform” rating reiterated by analysts at Mizuho in a research report issued on Friday, Benzinga reports. They currently have a $74.00 price objective on the biopharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of 243.87% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 10th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Corbus Pharmaceuticals in a report on Tuesday, August 6th. B. Riley initiated coverage on Corbus Pharmaceuticals in a research note on Wednesday, June 26th. They set a “buy” rating and a $85.00 price target for the company. Lifesci Capital upgraded shares of Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, August 21st. Finally, Oppenheimer lifted their price objective on Corbus Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Corbus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $72.29.

Corbus Pharmaceuticals Stock Performance

Shares of NASDAQ CRBP traded down $30.18 during mid-day trading on Friday, reaching $21.52. The company had a trading volume of 7,946,569 shares, compared to its average volume of 539,400. The stock has a market capitalization of $229.98 million, a PE ratio of -3.09 and a beta of 2.56. Corbus Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $61.90. The stock’s 50 day moving average is $55.82 and its 200-day moving average is $47.05.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.19) by $0.29. On average, sell-side analysts anticipate that Corbus Pharmaceuticals will post -3.77 EPS for the current year.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Several hedge funds have recently made changes to their positions in CRBP. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Corbus Pharmaceuticals during the 1st quarter worth approximately $976,000. Vanguard Group Inc. lifted its holdings in shares of Corbus Pharmaceuticals by 143.7% during the 1st quarter. Vanguard Group Inc. now owns 437,264 shares of the biopharmaceutical company’s stock worth $17,158,000 after acquiring an additional 257,808 shares during the period. Altitude Crest Partners Inc. acquired a new stake in shares of Corbus Pharmaceuticals during the 1st quarter valued at about $4,069,000. Price T Rowe Associates Inc. MD bought a new stake in Corbus Pharmaceuticals in the first quarter valued at about $7,554,000. Finally, Janus Henderson Group PLC acquired a new position in Corbus Pharmaceuticals in the first quarter worth about $13,363,000. Institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.